PC
AZN icon

Promus Capital’s AstraZeneca AZN Stock Holding History

Promus Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-637
Closed -$89K – 314
2025
Q2 		$89K Hold
637
– – 0.06% 120
2025
Q1 		$93.6K Hold
637
– – 0.07% 105
2024
Q4 		$83.4K Buy
+637
New +$89.2K 0.06% 113

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Promus Capital's AZN Position: Q3 2025 in Review

Promus Capital sold out of AstraZeneca (AZN) in Q3 2025, closing a stake of 637 shares — an estimated $89K sold.

Promus Capital first reported a position in AZN in Q4 2024 and held it in 3 quarters. The position peaked at $93.6K in Q1 2025. 1,288 funds tracked by Wall St. Rank hold AZN as of Q3 2025.

  • Promus Capital reported no remaining AstraZeneca position as of Q3 2025 after selling out during the quarter.
  • Promus Capital sold 637 AstraZeneca shares in Q3 2025, an estimated $89K.
  • Promus Capital first reported a position in AstraZeneca in Q4 2024 and held it in 3 quarters.
  • Promus Capital's AstraZeneca position peaked at $93.6K in Q1 2025.
  • 1,288 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2025.

Based on Promus Capital's 13F filing for Q3 2025, filed 13 Nov 2025.